Leukocyte (e.g., Lymphocyte, Granulocyte, Monocyte, Etc.) Patents (Class 435/7.24)
  • Publication number: 20130230525
    Abstract: Provided herein in certain embodiments are polypeptide complexes capable of binding to an antigen. Pharmaceutical compositions, method of using the polypeptide complexes are also provided.
    Type: Application
    Filed: November 9, 2011
    Publication date: September 5, 2013
    Applicant: ALTIMAB THERAPEUTICS, INC.
    Inventors: Zijuan Li, Chun Wu, Jun Bao, Bo Chen
  • Publication number: 20130230867
    Abstract: A composition for evaluating a biological condition is disclosed. The composition has (a) a sample composition comprising at least one of: i.) a bodily specimen comprising a target moiety; ii.) a positive control moiety; and iii.) a negative control moiety; (b) an antibody composition comprising at least one of: i.) at least one target antibody; ii.) at least one positive control identifying antibody; and iii.) at least one negative control identifying antibody; and (c) at least one reference composition comprising at least one of: i.) a target signal reference composition; and ii.) a reference identifier composition.
    Type: Application
    Filed: January 8, 2013
    Publication date: September 5, 2013
    Applicant: Trillium Diagnostics, LLC
    Inventors: Bruce H. Davis, Charles Bruce Bagwell, Benjamin Hunsberger
  • Patent number: 8524250
    Abstract: The present invention is directed to providing a carrier which can transport a compound to a gut-associated lymphoid tissue efficiently without being degraded or digested. For that purpose, the carrier contains a coccoid cell of a gastric mucosa-damaging spiral bacterium. Preferably, the carrier is orally administered. By making this carrier carry an antigen and orally administering it, a local or a systemic immunological reaction to the antigen can be induced.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: September 3, 2013
    Assignee: Keio University
    Inventors: Shigeo Koyasu, Shigenori Nagai, Chihiro Sasakawa, Hitomi Mimuro
  • Patent number: 8524467
    Abstract: The present invention relates to methods of identifying candidate compounds for the treatment of leukemia and diagnostic methods based on histone methylation and HoxA5 promoter activity.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: September 3, 2013
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Yi Zhang, Yuki Okada
  • Patent number: 8524505
    Abstract: The present invention provides a blood analyzer and a blood analyzing method capable of obtaining information regarding B lymphocytes and T lymphocytes without using a fluorescence-labeled antibody. The blood analyzer of the present invention includes a blood specimen supplying portion, a sample preparation portion that prepares a measurement sample without using a fluorescence-labeled antibody by mixing a blood specimen supplied from the blood specimen supplying portion, a hemolyzing agent, and a fluorescent dye that stains nucleic acid, a light source, a first detector that detects fluorescence, a second detector that detects scattered light, and information processing portion that classifies lymphocytes based on the intensity of fluorescence and scattered light, and based on the fluorescence intensity of the classified lymphocytes, obtains information regarding B-lymphocytes and T-lymphocytes.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: September 3, 2013
    Assignee: Sysmex Corporation
    Inventors: Mari Kono, Yuri Takagi, Shoichiro Asada
  • Publication number: 20130217038
    Abstract: The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event.
    Type: Application
    Filed: March 19, 2013
    Publication date: August 22, 2013
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventor: University of Pittsburgh - Of the Commonwealth System of Higher Education
  • Patent number: 8513028
    Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: August 20, 2013
    Assignee: Creagene Inc.
    Inventors: Jin Ah Jang, Dae Seog Lim, Hyun Soo Lee, Yong Soo Bae
  • Publication number: 20130209988
    Abstract: Methods and systems for selectively capturing analytes, such as cells, e.g., circulating tumor cells (CTCs), from fluid samples are disclosed. The methods include contacting the sample with an analyte binding moiety that selectively binds to the analytes; optionally separating first components of the sample including a majority of the analytes bound to the binding moieties from second components of the sample using size-based separation, e.g.
    Type: Application
    Filed: November 23, 2010
    Publication date: August 15, 2013
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Thomas A. Barber, Ajay Shah, John Walsh, Mehmet Toner, Ravi Kapur, Shannon L. Stott
  • Patent number: 8507237
    Abstract: The invention concerns a device and a method for concentrating pathogenic germs potentiaily present in blood products or derivatives and for detecting said germs comprising the following steps: (a) subjecting a sample of said blood product to a blood cell aggregating treatment, (b) eliminating the aggregates formed at step (a) by passing the treated sample over a first filter allowing through the contaminating germs but not the cell aggregates, (c) selectively lyzing the residual cells of the filtrate obtained at step (b), (d) recuperating the contaminating germs by passing the lysate of step (c) over a second filter to detect the contaminating germs possibly trapped.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: August 13, 2013
    Assignee: GeneOhm Sciences, Inc.
    Inventors: Jean-Pierre Hermet, Isabelle Besson-Faure, Sébastien Ribault, Yann Godfrin, Anne Monnot des Angles
  • Publication number: 20130203624
    Abstract: This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of prenatal or pregnancy-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of prenatal or pregnancy-related diseases or conditions.
    Type: Application
    Filed: July 22, 2011
    Publication date: August 8, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventor: Amin I. Kassis
  • Publication number: 20130202602
    Abstract: The present disclosure relates to anti-CD200 antibodies (e.g., variant anti-CD200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce a desired immunomodulatory effect in the human and/or selecting an appropriate dosing schedule for a patient.
    Type: Application
    Filed: January 11, 2011
    Publication date: August 8, 2013
    Applicant: Alexion Pharmaceuticals ,Inc.
    Inventors: Susan Faas McKnight, Roxanne Cofiell, Yan Yan
  • Publication number: 20130202552
    Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membrane signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.
    Type: Application
    Filed: February 11, 2013
    Publication date: August 8, 2013
    Applicant: APOTECH RESEARCH AND DEVELOPMENT LIMITED
    Inventor: APOTECH RESEARCH AND DEVELOPMENT LIMITED
  • Patent number: 8501424
    Abstract: The present invention provides CD4+ T-cell epitopes in bone morphogenetic proteins (BMPs). In particular embodiments, the present invention provides CD4+ T-cell epitopes of BMP-7 and BMP-14. In some preferred embodiments, the present invention provides CD4+ T-cell epitopes of BMP-7 and BMP-14 that are suitable for modification to reduce the immunogenicity of the BMP-7 and BMP-14 proteins.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: August 6, 2013
    Assignee: Danisco US Inc.
    Inventor: Fiona A. Harding
  • Patent number: 8501425
    Abstract: A method and apparatus for analyzing a sputum cytology preparation. The sputum sample is fixed on a microscope slide and analyzed by a microscope combined with an image acquisition system and a computer having an image recognition system. The image recognition system detects mobile cells that are implicated in the body's inflammatory response and counts how many of such cells are on the slide. The computer generates an absolute number of such cells and percentage values for such cells out the total number of mobile cells classified. The computer then utilizes the absolute numbers, the ratios of mobile cells with respect to each other—or a combination of both to generate a score. The score represents a probabilistic determination of inflammation.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: August 6, 2013
    Inventors: Mark Rutenberg, Richard Scott, Stephen Frist
  • Publication number: 20130195854
    Abstract: The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
    Type: Application
    Filed: January 29, 2013
    Publication date: August 1, 2013
    Applicant: ROCHE GLYCART AG
    Inventor: ROCHE GLYCART AG
  • Publication number: 20130189696
    Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence.
    Type: Application
    Filed: March 18, 2013
    Publication date: July 25, 2013
    Applicants: DRK BLUTSPENDEDIENST WEST GMBH, ERNST-MORITZ-ARNDT-UNIVERSITAT GREIFSWALD
    Inventors: Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
  • Publication number: 20130189284
    Abstract: Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes.
    Type: Application
    Filed: July 14, 2011
    Publication date: July 25, 2013
    Applicant: Technion Research & Development Foundation Ltd.
    Inventors: Yoram Reiter, Rony Dahan
  • Patent number: 8492347
    Abstract: The present invention relates to D-amino acid peptides and their use in methods for the diagnosis and/or treatment of immune disorders such as systemic lupus erythematosus.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: July 23, 2013
    Assignee: The Regents of the University of California
    Inventors: Bevra H. Hahn, Fanny M. Ebling, Antonio La Cava, Ram Raj Singh, Ram Pyare Singh
  • Publication number: 20130183686
    Abstract: Provided is a method for determining immunosuppression in an individual. The method entails testing blood cells for nuclear NFkB and/or nuclear NFAT. The blood cells can be from a sample of blood from an individual. The cells can be contacted with an activating agent to obtain activated cells, and the amount of nuclear NFkB and/or NFAT can be compared to a control. An amount of nuclear NFkB and/or NFAT that is higher than the control is considered to be indicative of insufficient immunosuppression in the individual. An amount of nuclear NFkB and/or NFAT that is lower than the control is considered to be indicative of excessive immunosuppression in the individual. An amount of nuclear NFkB and/or NFAT that is the same as the control is considered to be indicative of an appropriate amount of immunosuppression in the individual.
    Type: Application
    Filed: October 31, 2012
    Publication date: July 18, 2013
    Inventors: Oleh G. Pankewycz, Mark R. Laftavi, Hans Minderman
  • Patent number: 8486694
    Abstract: The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: July 16, 2013
    Assignees: Helmholtz Zentrum Muenchen Deutsches Forschungzentrum fuer Gesundheit und Umwelt GmbH, Max-Delbrueck-Centrum fuer Molekulare Medizin
    Inventors: Dolores Schendel, Susanne Wilde, Thomas Blankenstein
  • Patent number: 8486657
    Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: July 16, 2013
    Inventors: Xiaohong Cai, Thomas Cai
  • Patent number: 8486721
    Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: July 16, 2013
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Graham Davis
  • Publication number: 20130178835
    Abstract: The present invention provides for the identification of autoreactive T cell populations from individuals having autoimmune diseases, such as multiple sclerosis and EAE. Peptoids recognized by autoreactive T cells can be used to identify various types of autoimmune disease, and can also be used to target therapies against such populations.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 11, 2013
    Applicant: The Board of Regents of the University of Texas System
    Inventor: The Board of Regents of the University of Texas System
  • Publication number: 20130171668
    Abstract: The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II ? chain; (ii) all or part of the extracellular portion of an MHC class II ? chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the ?2 domain of said ? chain and the ?2 domain of said ? chain, wherein said cysteine residues are not present in native MHC class II ?2 and ?2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects.
    Type: Application
    Filed: February 18, 2011
    Publication date: July 4, 2013
    Applicant: Universitetet I Oslo
    Inventor: Geir Age Loset
  • Patent number: 8476028
    Abstract: There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: July 2, 2013
    Assignee: King's College London
    Inventors: Kenneth Alun Brown, Sion Marc Lewis
  • Publication number: 20130156729
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: February 7, 2013
    Publication date: June 20, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: Merck Sharp & Dohme Corp.
  • Patent number: 8465937
    Abstract: The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 18, 2013
    Assignee: ESBATech, an Alcon Biomedical Research Unit, LLC
    Inventors: David Urech, Valerie Hulmann-Cottier
  • Publication number: 20130150252
    Abstract: The present invention is drawn to methods for measuring numbers, levels, and/or ratios of cells, such as lymphocytes, infiltrated into a solid tissue, such as a tumor or a tissue affected by an autoimmune disease, and to methods for making patient prognoses based on such measurements. In one aspect, methods of the invention comprise sorting lymphocytes from an accessible tissue, such as peripheral blood, into functional subsets, such as cytotoxic T cells and regulatory T cells, and generating clonotype profiles of each subset. An inaccessible disease-affected tissue is sampled and one or more clonotype profiles are generated. From the latter clonotype profiles, levels lymphocytes in each of the functional subsets are determined in the disease-affected tissue by their clonotypes, which are identified from lymphocytes sorted into subsets from the accessible tissue.
    Type: Application
    Filed: November 29, 2012
    Publication date: June 13, 2013
    Applicant: SEQUENTA, INC.
    Inventor: Sequenta, Inc.
  • Publication number: 20130149719
    Abstract: The present invention is directed to proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents.
    Type: Application
    Filed: June 21, 2011
    Publication date: June 13, 2013
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventor: Maria L. Gennaro
  • Patent number: 8461304
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: June 11, 2013
    Assignee: Affitech Research AS
    Inventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
  • Publication number: 20130142787
    Abstract: Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-B cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. In other embodiments, optimal dosages of therapeutic antibody may be selected by monitoring the degree of trogocytosis induced by anti-B cell antibodies.
    Type: Application
    Filed: December 4, 2012
    Publication date: June 6, 2013
    Applicant: IMMUNOMEDICS, INC.
    Inventor: Immunomedics, Inc.
  • Patent number: 8455209
    Abstract: The present invention provides a reagent for analysis of immature leukocytes comprising: a surfactant which can damage cell membranes of erythrocytes and mature leukocytes, a solubilizing agent which can shrink the damaged blood cells and a dye for staining nucleic acid, wherein the reagent has an osmotic pressure of not lower than 10 mOsm/kg and lower than 150 mOsm/kg.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: June 4, 2013
    Assignee: Sysmex Corporation
    Inventors: Yukiko Kataoka, Tomohiro Tsuji, Shinichiro Oguni, Ayumu Yoshida, Masaki Abe
  • Patent number: 8455227
    Abstract: This invention provides methods for to the use of the difference in phosphodiester (PDE)/phosphomonoester (PME) ratio in biological fluids, as an analytical criterion to image both the presence and degree of viral infection in-vivo.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: June 4, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Tomasz Rozmyslowicz, Krzysztof Wroblewski, Glen N. Gaulton
  • Publication number: 20130136754
    Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.
    Type: Application
    Filed: August 4, 2011
    Publication date: May 30, 2013
    Inventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
  • Publication number: 20130129748
    Abstract: The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 23, 2013
    Applicant: Viral Logic Systems Technology Corp.
    Inventors: Steven Wiley, Craig A. Smith, Ajamete Kaykas
  • Publication number: 20130122524
    Abstract: This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of a cell present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens.
    Type: Application
    Filed: November 8, 2012
    Publication date: May 16, 2013
    Applicant: Nodality, Inc.
    Inventor: Nodality, Inc.
  • Publication number: 20130122523
    Abstract: An in-vitro process for the quick determination of the infection status of a Mycobacterium tuberculosis infection from whole blood in terms of active or latent tuberculosis, comprising the steps of: stimulating an antigen-specific T cell that is present in a first sample of whole blood with purified protein derivative (PPD) in the presence of antibodies against CD28, or CD28 and CD49d; processing of PPD by antigen-presenting cells (APC) by incubating for 1.5 h to 2.5 h, especially for 2 h, at 35° C. to 39° C., especially at 37° C., optionally with adding CO2; then adding a secretion inhibitor; effecting an intensive mixing; and another incubation for a period of at least 2.5 h at a temperature of from 35° C. to 39° C.
    Type: Application
    Filed: March 21, 2011
    Publication date: May 16, 2013
    Inventors: Ferdinand Hermann Bahlmann, Danilo Fliser, Martina Sester, Urban Sester
  • Publication number: 20130123145
    Abstract: Multiplexed assays are disclosed for detection of duster differentiation 4 (CD4) glycoprotein expressed on the cell surface of I-helper cells, monocytes, macrophages, and dendritic cells; cluster differentiation 25 (CD25), a type transmembrane protein present on activated T-cells, activated B-cells, thymocytes, myeloid precursors, and oligodendrocytes; and Forkhead box P3 (FOXP3), an intracellular protein involved in immune system responses in cell cultures, tissues samples, humans, and biological samples. The multiplexed assays can be used to detect 1r-cells, activated I-cells, and other similar cell types (e.g. natural T regulatory cells, adaptive/induced T regulatory T cells). The multiplexed assays employ quantum dots of various shapes, types, compositions, coatings, sizes, ligands and other such characteristics.
    Type: Application
    Filed: December 22, 2012
    Publication date: May 16, 2013
    Applicant: NNANOAXIS, LLC
    Inventors: Krishnan Chakravarthy, Siddhartha Kamisetti
  • Publication number: 20130121914
    Abstract: The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided.
    Type: Application
    Filed: June 2, 2011
    Publication date: May 16, 2013
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Koichi Kino, Toshihiro Kai, Mitsuhiro Matsumoto, Masunori Kajikawa, Masahito Sugiura, Emi Shimizu
  • Publication number: 20130115630
    Abstract: Embodiments relate generally to an automated multiplex immunoassay for qualitatively and/or quantitatively detecting a plurality of targets on a tissue sample. Kits and apparatuses for practicing such assays are also provided.
    Type: Application
    Filed: November 9, 2011
    Publication date: May 9, 2013
    Inventors: Paul Shore, Louisa Poole, Justine Reed
  • Publication number: 20130109032
    Abstract: The present invention is directed to methods of using biomarkers to assess treatment of gastrointestinal inflammatory disorders with beta7 antagonists. More particularly, the present invention relates to methods of using the level of gut-homing lymphocytes in peripheral blood, the level of drug occupancy on gut-homing lymphocytes, and/or the level of beta7 integrin receptors on gut-homing lymphocytes as indicators (or biomarkers) of the effect, efficacy, safety, prognosis, and/or dosing of therapeutic agents, such as beta7 integrin antagonists, for the treatment of gastrointestinal inflammatory disorders.
    Type: Application
    Filed: September 16, 2011
    Publication date: May 2, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Patent number: 8426141
    Abstract: The present invention relates to methods for increasing the therapeutic efficacy of immunoglobulin G class 3 (IgG3) antibodies, immunoglobulin G class 3 (IgG3) antibodies with an improved therapeutic efficacy and the use thereof as a medicament, in particularly a medicament for immunotherapy. Specifically, the present invention relates to methods for increasing the therapeutic efficacy of an immunoglobulin G class 3 (IgG3) antibody comprising providing a mutated immunoglobulin G class 3 (IgG3) antibody, wherein the mutation, as compared to the parent immunoglobulin G class 3 (IgG3) antibody, comprises a replacement of the amino acid arginine (R) at position 435 in the CH3 domain with the amino acid histidine (H), and antibodies obtained by the present methods and their use as a medicament.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: April 23, 2013
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventors: Gestur Vidarsson, Catherine E. Van der Schoot
  • Patent number: 8426144
    Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: April 23, 2013
    Assignee: Merck & Sharp & Dohme Corp.
    Inventors: Elizabeth Bates, Nathalie Fournier, Lionel Chalus, Pierre Garrone
  • Publication number: 20130096024
    Abstract: An in vitro method for the analysis of the genetic predisposition of an individual to develop adverse effects related to non-metallic materials implanted into the body. The method comprises determining if in a biological sample from an individual there is/are present the antigen/s HLA-B*08 and/or HLA-DRB1*03 of the major histocompatibility complex. The use of a kit for carrying out the determination and the use of the antigens as genetic markers is also disclosed.
    Type: Application
    Filed: April 21, 2011
    Publication date: April 18, 2013
    Applicant: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
    Inventors: Simón Schwartz Navarro, Jaume Alijotas Reig
  • Publication number: 20130096016
    Abstract: The invention relates to a method for quantitatively identifying relevant HLA-bound peptide antigens from primary tissue specimens on a large scale without labeling approaches. This method can not only be used for the development of peptide vaccines, but is also highly valuable for a molecularly defined immunomonitoring and the identification of new antigens for any immunotherapeutic strategy in which HLA-restricted antigenic determinants function as targets, such as a variety of subunit vaccines or adoptive T-cell transfer approaches in cancer, or infectious and autoimmune diseases.
    Type: Application
    Filed: April 15, 2011
    Publication date: April 18, 2013
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Jens Fritsche
  • Publication number: 20130090456
    Abstract: The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 11, 2013
    Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC
    Inventors: David Urech, Valerie Hulmann-Cottier
  • Patent number: 8409818
    Abstract: The invention provides kits and methods for detecting or monitoring the number of cells in sample. The cell comprises a cell surface associated protein (CSAP) comprising a cytoplasmic (cytosolic) and an extracellular (ecto) domain. The kit comprises: (i) a chromatographic device; and (ii) a CSAP-binding agent. The method comprises: (i) optionally contacting the sample with an agent capable of lysing or permeabilizing CSAP bearing cells; (ii) contacting the sample with a CSAP-binding agent that binds to the cytoplasmic domain of the CSAP; and (iii) directly or indirectly evaluating the level or presence of bound CSAP in the sample.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: April 2, 2013
    Assignee: The Macfarlane Burnet Institute for Medical Research and Public Health Limited
    Inventors: David Andrew Anderson, Robyn Elizabeth Lloyd, Suzanne Mary Crowe, Mary Louise Garcia, Alan Lee Landay
  • Publication number: 20130071860
    Abstract: In one aspect, the present invention provides methods for the classification, diagnosis, prognosis, theranosis, and/or prediction of an outcome of an autoimmune disease in a subject.
    Type: Application
    Filed: February 24, 2011
    Publication date: March 21, 2013
    Inventors: Matthew B. Hale, Jason Ptacek, Garry P. Nolan
  • Patent number: 8399206
    Abstract: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: March 19, 2013
    Assignee: Nodality, Inc.
    Inventors: Wendy J. Fantl, David B. Rosen, Alessandra Cesano, Santosh K. Putta, James R. Hackett, Michael Walker, Jing Shi
  • Patent number: 8399208
    Abstract: The present invention is related to accurate detection methods for the measurement only of myeloperoxidase (MPO) levels or neutrophils, preferably equine neutrophils, in complex biological samples. The present invention is further related to ELISA and SIEFED assays for such detection. SIEFED detection sensitivity of active peroxidase activity was found to be enhanced by the addition of nitrite. Such MPO measurement finds its use in many applications such as the prediction, diagnosis and/or monitoring of pathologies correlated with neutrophil activation and/or destruction; the evaluation of drugs and/or immunomodulators; the assessment of immune responses, either natural and/or after treatment with immunomodulators and/or drugs; and the study of cells and their ability to fight microorganisms and/or to destroy them.
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: March 19, 2013
    Assignee: Universite de Liege
    Inventors: Didier Serteyn, Ginette Dupont, Thierry Franck, Stéphane Kohnen